Clinical trial · Observational
CX3CR1+T Cell Predict Immunotherapy Efficacy
Prediction of Immunotherapy Efficacy Based on Transcriptome of CX3CR1+T Cell in Peripheral Blood
NCT06054152CI-TRIAL-00091383completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aimed to evaluate the correlation between the proportion of flow-sorted CX3CR1+T cells in peripheral blood and the CX3CR1+T-specific gene signature and the efficacy of immunotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PD-1 inhibitor based immunotherapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- objective response rate（ORR）
- timeFrame
- 4 weeks
- description
- Imaging findings of CR, PR, and stable disease (SD) in all subjects evaluated according to RECIST V1.1 after completing 4 cycles of immunotherapy. best overall response (BoR) was evaluated in participants achieving complete and partial response.
Secondary outcomes (2)
- measure
- progression-free survival (PFS)
- timeFrame
- 1 year
- description
- progression-free survival (PFS) defined as time from surgery until disease progression or death from any cause
- measure
- overall survival (OS)
- timeFrame
- 1 year
- description
- Overall survival (OS) was defined as the time from surgery until death from any cause
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. At least 18 years old; 2. Diagnosed as Non-small cell lung cancer by biopsy before treatment; 3. Prepare to receive PD(L)1 inhibitor monotherapy or combined chemotherapy and antivascular drugs; 4. Lesion imaging can be measured and evaluated by RECIST1.1 standard; 5. Life expectancy exceeds 3 months; 6. ECOG score 0-2; 7. The newly IO treated patients did not receive immunotherapy, chemoradiotherapy before participate in the trial; 8. Sign informed consent and be willing to provide 5ml of peripheral blood for research Exclusion Criteria: 1. Genetic test showed EGFR and ALK mutations; 2. Patients with other co-morbidities that may affect their follow-up and short-term survival; 3. Patients with any history of antitumor therapy; 4. Patients with a history of other systemic tumors; 5. The ineligible participants assessed by the researchers
References
Publications (3)
- BACKGROUNDZheng L, Qin S, Si W, Wang A, Xing B, Gao R, Ren X, Wang L, Wu X, Zhang J, Wu N, Zhang N, Zheng H, Ouyang H, Chen K, Bu Z, Hu X, Ji J, Zhang Z. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science. 2021 Dec 17;374(6574):abe6474. doi: 10.1126/science.abe6474. Epub 2021 Dec 17. PMID 34914499
- BACKGROUNDYamauchi T, Hoki T, Oba T, Jain V, Chen H, Attwood K, Battaglia S, George S, Chatta G, Puzanov I, Morrison C, Odunsi K, Segal BH, Dy GK, Ernstoff MS, Ito F. T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors. Nat Commun. 2021 Mar 3;12(1):1402. doi: 10.1038/s41467-021-21619-0. PMID 33658501
- DERIVEDDong Y, Xu X, Si H, Li Y, Yang D, Chen J, Wang Y, Zhang HM, Yang L, Xie H, Yang M, Shi B, Zhao D, Hu X, Wen J, Xu L, Wu J, Chen C. A machine learning model integrating circulating Temra cell transcriptional profiles to predict immunotherapy efficacy. Med. 2026 Apr 10;7(4):101027. doi: 10.1016/j.medj.2026.101027. Epub 2026 Feb 25. PMID 41747737